Company news
Aurisco Pharmaceutical Co. Ltd. Class A (SSE:605116) news
Aurisco Pharmaceutical Co. Ltd. Class A news releases on 6ix. Latest, Aug 29, 2026: "Aurisco Pharmaceutical Co., Ltd."Announcement on Convening the 2026…
Press releases & updates
"Aurisco Pharmaceutical Co., Ltd."Announcement on Convening the 2026 Semi-annual Performance Briefing
August 28, 2026
"Aurisco Pharmaceutical Co., Ltd."Announcement on Obtaining Notice of Approval for Drug Supplementary Application by a Wholly-owned Subsidiary
August 24, 2026
"Aurisco Pharmaceutical Co., Ltd."Announcement on the Wholly-owned Subsidiary Passing the U.S. FDA On-Site Inspection
August 12, 2026
"Aurisco Pharmaceutical Co., Ltd."Announcement on the Proposed Selection of the Company's Products in the 12th Batch of National Centralized Drug Procurement
August 3, 2026
"Aurisco Pharmaceutical Co., Ltd."Announcement on 2026 Interest Payment for "Aurisco Convertible Bonds"
July 20, 2026
"Aurisco Pharmaceutical Co., Ltd."Announcement on Inclusion of the Company's Main Products in the "National Essential Medicines List (2026 Edition)"
July 15, 2026
"Aurisco Pharmaceutical Co., Ltd."Announcement on Passing GMP Compliance Inspection for Drugs
July 13, 2026
"Aurisco Pharmaceutical Co., Ltd."Announcement on Conversion Result of Convertible Bonds and Share Changes
July 1, 2026
Correction Announcement on Progress in Providing Guarantee for Wholly-owned Subsidiary
June 15, 2026
Announcement on Progress in Providing Guarantee for Wholly-owned Subsidiary
June 12, 2026
Announcement on Not Revising Downward Conversion Price of ""Aurisco Convertible Bonds"
June 11, 2026
Announcement on Adjusting the Conversion Price of "Aurisco Convertible Bonds" Due to Implementation of Dividend Distribution
June 7, 2026
Indicative Announcement on ""Aurisco Convertible Bonds"" Expected to Meet Conditions for Revising Conversion Price
June 4, 2026
Indicative Announcement on Suspending Conversion of "Aurisco Convertible Bonds" When Implementing Dividend Distribution for 2025
June 1, 2026
Announcement on Obtaining Drug Registration Approval by the Company
May 11, 2026
Announcement on Resolutions of the 1st Meeting of the 4th Board of Directors
May 7, 2026
Report for Q1 2026
April 23, 2026
Announcement on the Estimated External Guarantee Limit
April 16, 2026
Announcement on Conversion Result of Convertible Bonds and Share Changes
April 1, 2026
Announcement on Results of Share Reduction by Director
March 31, 2026
Announcement on the Company Certified as High-tech Enterprise
March 20, 2026
Indicative Announcement on Change in Equity of Shareholders with Over 5% Shares Reaching 1% Scale
March 17, 2026
Announcement on Shareholding Reduction Plan for Partial Board of Directors
January 30, 2026
Announcement on Implementation Result of Shares Repurchase and Share Changes
January 21, 2026
Announcement on Adjusting Upper Limit of Repurchase Price
January 12, 2026
Announcement on Progress in Repurchasing Shares through Call Auction
January 4, 2026
Announcement on the Implementation of Repurchase and Cancellation of Partial Restricted Stocks
December 30, 2025
Announcement on Result of Shareholding Reduction by Shareholder
December 24, 2025
Announcement on Passing GMP Compliance Inspection for Drugs
December 18, 2025
Announcement on Result of Shareholding Reduction by Senior Management Members
November 26, 2025
Announcement on Obtaining Drug Registration Approval by the Wholly-owned Subsidiary
November 25, 2025
Announcement on Convening the Q3 2025 Performance Briefing
November 14, 2025
Announcement on Shareholding Reduction Plan for Shareholders
November 4, 2025
Announcement on Achieving Conditions for Lifting Sales Restrictions and Listing of the 3rd Restricted Stock Trading Period under the 2022 Restricted Stock Incentive Plan
October 30, 2025
Announcement on Resolutions of the 1st Extraordinary General Meeting in 2025
September 26, 2025
Announcement on Change of Sponsor Representative for Continuous Supervision
September 18, 2025
Announcement on Listing and Circulation of Partial Restricted Shares in Initial Public Offering
September 12, 2025
Announcement on Redemption of Partial Idle Raised Funds Used for Cash Management upon Expiration and Continuously Conducting Cash Management
September 1, 2025
Announcement on Convening the 2025 Semi-annual Performance Briefing
August 28, 2025
Announcement on Shareholding Reduction Plan for Partial Senior Executives
August 4, 2025
Announcement on Redemption upon Maturity of Partial Idle Raised Funds Used for Cash Management
July 31, 2025
Announcement on Interest Payment for "Aurisco Convertible Bonds" in 2025
July 21, 2025
Announcement on 2025 Tracking Credit Rating Results of "Aurisco Convertible Bonds"
June 27, 2025
Announcement on Passing On-site Inspection by FDA
June 18, 2025
Announcement on Adjusting Upper Limit of Shares Repurchase Price after Implementing Dividend Distribution for 2024
June 13, 2025
Announcement on Adjusting the Total Cash Dividends for Profit Distribution in 2024
June 12, 2025
Indicative Announcement on Suspending Conversion of "Aurisco Convertible Bonds" during Implementation of Dividend Distribution for 2024
June 6, 2025
Announcement on Resolution of the 2024 Annual General Meeting
May 16, 2025
Announcement on Change in Bondholders' Holding Ratio of Convertible Bonds Reaching 10%
May 8, 2025
Announcement on Progress of Using Some Idle Raised Funds for Cash Management
May 6, 2025